ABSTRACT
In the fight against the COVID-19 pandemic, lockdowns have succeeded in limiting contagions in many countries, at however heavy societal costs: more targeted non-pharmaceutical interventions are desirable to contain or mitigate potential resurgences. Contact tracing, by identifying and quarantining people who have been in prolonged contact with an infectious individual, has the potential to stop the spread where and when it occurs, with thus limited impact. The limitations of manual contact tracing (MCT), due to delays and imperfect recall of contacts, might be compensated by digital contact tracing (DCT) based on smartphone apps, whose impact however depends on the app adoption. To assess the efficiency of such interventions in realistic settings, we use here datasets describing contacts between individuals in several contexts, with high spatial and temporal resolution, to feed numerical simulations of a compartmental model for COVID-19. We find that the obtained reduction of epidemic size has a robust behavior: this benefit is linear in the fraction of contacts recalled during MCT, and quadratic in the app adoption, with no threshold effect. The combination of tracing strategies can yield important benefits, and the cost (number of quarantines) vs. benefit curve has a typical parabolic shape, independent on the type of tracing, with a high benefit and low cost if app adoption and MCT efficiency are high enough. Our numerical results are qualitatively confirmed by analytical results on simplified models. These results may inform the inclusion of MCT and DCT within COVID-19 response plans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially supported by the Lagrange Project of the ISI Foundation funded by CRT Foundation to CC. It was partially supported by the ANR project DATAREDUX (ANR-19-CE46-0008-01) to AB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We use only publicly available data and no IRB is needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is publicly available
